And Lu Liu

And Lu Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Applied Sciences
Verified
Journal Article
Open access
PDF file
QGqi wen Gao
qi wen Gao
YWYouxue Wang
Youxue Wang
YYYang Yang
Yang Yang
SPSanxi Peng
Sanxi Peng
SYSongping Yu
Songping Yu
LYLei Yan
Lei Yan
We used the ray tracing technique based on the IASP91 Earth model to calculate the travel times in order to identify the phases. This technique can calculate the travel times for the seismic phases in the conventional travel time tables. The waveform data received from the stations in the Guangxi area are selected for analysis and discussion. The outcomes of the numerical modeling and its use demonstrate that there is good agreement in terms of the absolute differences between the calculated and theoretical travel times from the ISAP91 tables. The relative residuals are determined directly from the actual arrival times picking during the correlation analysis, and the validity of the travel time method for picking seismic phases by correlation analysis can be demonstrated.

4 November 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
ZQZhonghua Qi
Zhonghua Qi
MWMiaolei Wang
Miaolei Wang
HMHong Ma
Hong Ma
ALAnd Lu Liu
And Lu Liu
JLJunhong Liu
Junhong Liu
Irritable bowel syndrome is a disorder of gut–brain interaction characterized by recurrent abdominal pain and altered bowel habits. Interactions among intestinal microorganisms and their metabolites, the epithelial barrier, mucosal immunity, and gut–brain signaling provide important insights into the heterogeneity of this condition. Engineered micro- and nanoscale carriers may improve the stability of orally administered bioactive agents and facilitate local intestinal delivery while modulating relevant pathological processes through protection of viable microorganisms, delivery of microbial metabolites, or direct regulation of host cells. This review examines major mechanisms underlying microbiota–immune interactions and summarizes advances in colon-targeted delivery, protective carriers for probiotics, plant-derived vesicle-like preparations, and microalgae-based hybrid systems. We further discuss the biological characteristics of different clinical subtypes and key translational challenges, including safety, quality control, and rigorous verification of therapeutic efficacy. In particular, evidence from direct irritable bowel syndrome studies is distinguished from findings in symptom-based models, other disease models, and fundamental mechanistic experiments.